Welcome to our dedicated page for Connect Biopharma Holdings SEC filings (Ticker: CNTB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Connect Biopharma Holdings Limited (CNTB) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8-K and other key documents filed with the Securities and Exchange Commission. These filings give investors structured insight into the clinical, financial, and corporate events that shape this clinical-stage biopharmaceutical company focused on asthma, COPD, and related inflammatory diseases.
Connect Biopharma’s recent Forms 8-K have covered topics such as quarterly financial results, business updates, and material corporate actions. Examples include announcements of second and third quarter financial results, the initiation and progress of Phase 2 Seabreeze STAT asthma and COPD studies for rademikibart, and the company’s decision to terminate its American Depositary Receipt program and directly list its ordinary shares on the Nasdaq Global Market. Other 8-K filings describe board changes, including the appointment of an additional director, and regulatory milestones such as the submission of a New Drug Application for rademikibart in atopic dermatitis by the company’s exclusive licensee in China.
Filings also document insider-related information and regulatory disclosures under Regulation FD, such as updates on share purchases by senior executives and communications about collaboration activities with Simcere Pharmaceutical Co., Ltd. in Greater China. These documents complement Connect Biopharma’s press releases by providing formal, SEC-compliant descriptions of material events.
On Stock Titan, CNTB filings are updated as new documents are posted to the SEC’s EDGAR system. Users can review individual filings to understand how Connect Biopharma reports its clinical progress with rademikibart, capital markets decisions, governance changes, and other significant developments that may be relevant to an assessment of CNTB stock.
Ikarian Capital, LLC and Neil Shahrestani have disclosed an 8.8% passive stake in Connect Biopharma Holdings Limited. They report beneficial ownership of 4,933,086 ordinary shares, including 144,600 shares that can be acquired within 60 days through call options, based on 55,903,513 shares outstanding as of October 31, 2025.
The shares are held by Ikarian Healthcare Master Fund, L.P. and certain separately managed accounts for which Ikarian Capital acts as investment manager or sub-adviser. The filers certify the position is held in the ordinary course of business and state it was not acquired to change or influence control of Connect Biopharma.
Connect Biopharma (CNTB) reported Q3 2025 results with license and collaboration revenue of $16,000 and total operating expenses of $17.7 million, driven by research and development of $11.1 million and general and administrative of $6.6 million. The company posted a net loss of $17.2 million (basic and diluted loss per share $0.31). For the nine months, revenue was $64,000 and net loss was $40.4 million.
Cash, cash equivalents and short-term investments were $54.8 million as of September 30, 2025. Management believes these resources will fund anticipated needs for at least one year from the filing date. Total shareholders’ equity was $55.4 million.
In September, CNTB terminated its ADR program; ADRs were exchanged one-for-one into ordinary shares, which now trade on Nasdaq under “CNTB.” The company presented rademikibart data at ERS 2025 and is running Phase 2 studies in acute exacerbations of asthma and COPD, with topline data expected in the first half of 2026. As of October 31, 2025, 55,903,513 ordinary shares were outstanding.
Connect Biopharma Holdings Limited filed an 8-K stating it issued a press release announcing financial results for the three and nine months ended September 30, 2025. The press release is attached as Exhibit 99.1 and is incorporated by reference.
Per Item 2.02 and General Instruction B.2, the information, including Exhibit 99.1, is being furnished and not deemed filed under the Exchange Act. The company’s ordinary shares trade on the Nasdaq Global Market under the symbol CNTB.
Connect Biopharma Holdings Ltd (CNTB) filing a Form 144 notifies a proposed sale of 200,000 American Depositary Shares (ADS) on or about 10/01/2025 through Charles Schwab & Co on the Nasdaq Global Market. The ADS block has an aggregate market value of $305,940 and the company reports 55,721,657 shares outstanding. The securities were originally acquired on 03/19/2021 as a stock award issued as compensation, with no cash payment required. The filer reports no sales of issuer securities in the past three months and certifies they are unaware of any undisclosed material adverse information.
Connect Biopharma Holdings Limited filed a current report describing open-market share purchases by two senior executives over the past year. Chief Executive Officer Barry D. Quart, Pharm.D., bought a total of 224,034 company shares in multiple transactions between September 2024 and September 2025. President David Szekeres purchased a total of 215,739 shares in transactions occurring between November 2024 and September 2025. The company states that all of these purchases complied with its Insider Trading Compliance Policy and characterizes this information as furnished under Regulation FD, not filed for liability purposes.
Connect Biopharma (CNTB) reported a swing to loss as the company recorded a $23.2 million net loss for the six months ended June 30, 2025, compared with net income of $6.2 million in the prior-year period. Revenue from the Simcere license fell sharply to $48,000 in both the three- and six-month periods from $24.1 million a year earlier, driven by prior upfront and milestone recognition in 2024. Rademikibart progress remains central: the company presented clinical and preclinical data showing rapid FEV1 improvement and reduced exacerbations and reports that its China collaborator submitted an NDA for atopic dermatitis; Connect is eligible for up to $110 million in remaining milestones plus royalties.
Liquidity tightened: cash, cash equivalents and short-term investments totaled $71.8 million at quarter end and management states this is sufficient to meet anticipated cash requirements for at least one year from the filing. Operating cash use increased to $22.6 million for the six months, reflecting higher R&D as Phase 2 acute‑exacerbation trials were initiated and ongoing program investment continued.
Connect Biopharma Holdings Limited filed a current report to note that it has released its latest financial results. On August 13, 2025, the company issued a press release covering its results for the three and six months ended June 30, 2025, and attached that release as an exhibit to this report.
The filing itself mainly serves as a formal notice that the earnings press release is available and clarifies that this information is being "furnished" rather than "filed" under securities laws. The report is signed by Lisa Peraza, Senior Vice President, Finance, on behalf of the company.
Connect Biopharma (CNTB) has initiated the termination of its American Depositary Receipt (ADR) program. On 18 Jul 2025 the company instructed Deutsche Bank Trust Company Americas to end the 18 Mar 2021 Deposit Agreement. All ADRs will be mandatorily cancelled on or about 2 Sep 2025 and exchanged on a 1-for-1 basis for the underlying ordinary shares.
Immediately after cancellation, CNTB plans a direct listing of its ordinary shares on Nasdaq under the same ticker “CNTB,” at which point the ADSs will be delisted. The Depositary will send formal notice to ADS holders describing the exchange mechanics.
The change affects capital-markets logistics rather than operations: it removes depositary fees, simplifies share structure and may broaden investor access, but requires successful coordination with Nasdaq and could create short-term trading friction. No financial results or guidance were provided.